PROCF (Sofgen Pharma) Beneish M-Score: 0.00 (As of Sep. 07, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PROCF Sofgen Pharma SA PROCF
24 GF Score
Price $0.00
View Full Analysis

What is Sofgen Pharma Beneish M-Score?

Sofgen Pharma PROCF 24 Beneish M-Score is 0.00 as of Sep. 07, 2026. GuruFocus rates PROCF with a GF Score™ of 24/100.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Sofgen Pharma's Beneish M-Score or its related term are showing as below:

During the past 6 years, the highest Beneish M-Score of Sofgen Pharma was 0.00. The lowest was 0.00. And the median was 0.00.

Sofgen Pharma Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Sofgen Pharma's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sofgen Pharma Beneish M-Score Chart

Sofgen Pharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Beneish M-Score
Get a 7-Day Free Trial 0.00 -2.97 -2.71 0.00 0.00

Sofgen Pharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Dec24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.73 -2.78 -3.25 0.00 0.00

PROCF vs BKUH, ORGO, SIGA: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sofgen Pharma's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sofgen Pharma Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sofgen Pharma's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Sofgen Pharma's Beneish M-Score falls into.


PROCF
24GF Score
Sofgen Pharma SA PROCF
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sofgen Pharma Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Sofgen Pharma for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8544+0.528 * 1.031+0.404 * 1.2722+0.892 * 0.8453+0.115 * 1.2616
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9098+4.679 * -0.248943-0.327 * 1.2796
=-3.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec24) TTM:Last Year (Mar23) TTM:
Total Receivables was $103.3 Mil.
Revenue was 0 + 111.119 + 118.41 + 110.057 = $339.6 Mil.
Gross Profit was 0 + 62.323 + 68.403 + 61.188 = $191.9 Mil.
Total Current Assets was $216.7 Mil.
Total Assets was $411.7 Mil.
Property, Plant and Equipment(Net PPE) was $134.1 Mil.
Depreciation, Depletion and Amortization(DDA) was $14.5 Mil.
Selling, General, & Admin. Expense(SGA) was $150.6 Mil.
Total Current Liabilities was $415.9 Mil.
Long-Term Debt & Capital Lease Obligation was $41.4 Mil.
Net Income was 0 + -1.426 + 8.194 + 26.955 = $33.7 Mil.
Non Operating Income was 0 + -12.993 + 10.04 + 34.637 = $31.7 Mil.
Cash Flow from Operations was 0 + 36.703 + 47.394 + 20.43 = $104.5 Mil.
 Total Receivables was $143.0 Mil.
Revenue was 84.162 + 94.75 + 110.403 + 112.42 = $401.7 Mil.
Gross Profit was 46.062 + 47.814 + 67.558 + 72.634 = $234.1 Mil.
Total Current Assets was $268.8 Mil.
Total Assets was $441.7 Mil.
Property, Plant and Equipment(Net PPE) was $121.5 Mil.
Depreciation, Depletion and Amortization(DDA) was $17.1 Mil.
Selling, General, & Admin. Expense(SGA) was $195.8 Mil.
Total Current Liabilities was $233.5 Mil.
Long-Term Debt & Capital Lease Obligation was $150.0 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(103.25 / 339.586) / (142.97 / 401.735)
=0.304047 / 0.355881
=0.8544

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(234.068 / 401.735) / (191.914 / 339.586)
=0.582643 / 0.565141
=1.031

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (216.746 + 134.067) / 411.693) / (1 - (268.847 + 121.526) / 441.716)
=0.147877 / 0.116235
=1.2722

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=339.586 / 401.735
=0.8453

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(17.05 / (17.05 + 121.526)) / (14.488 / (14.488 + 134.067))
=0.123037 / 0.097526
=1.2616

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(150.557 / 339.586) / (195.77 / 401.735)
=0.443355 / 0.487311
=0.9098

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((41.407 + 415.924) / 411.693) / ((150.011 + 233.464) / 441.716)
=1.110854 / 0.868148
=1.2796

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(33.723 - 31.684 - 104.527) / 411.693
=-0.248943

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Sofgen Pharma has a M-score of -3.84 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of 0.00 mean?
Sofgen Pharma (PROCF) has a Beneish M-Score of 0.00 as of Sep. 07, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Sofgen Pharma and its competitors.
Is Sofgen Pharma's Beneish M-Score too high?
Sofgen Pharma's current Beneish M-Score is 0.00. Overall, Sofgen Pharma has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Sofgen Pharma's Beneish M-Score compare to BKUH and ORGO?
Sofgen Pharma's Beneish M-Score of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Sofgen Pharma and its competitors. Sofgen Pharma's current Beneish M-Score is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sofgen Pharma stock overvalued right now?
Sofgen Pharma (PROCF) has a current Beneish M-Score of 0.00. The current Beneish M-Score is 0.00. Sofgen Pharma's overall GF Score™ is 24/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Sofgen Pharma (PROCF), the current Beneish M-Score is 0.00 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sofgen Pharma Business Description

Address 9 Rue de Bitbourg, Luxembourg, LUX, L-1273
Procaps Group SA is an integrated healthcare and pharmaceutical company that develops and manufactures pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. The company's segment includes NextGel, Procaps Colombia, CAN, CASAND, and Diabetrics. It generates maximum revenue from the NextGel segment. It has geographic presence in Bolivia, Brazil, Colombia, Costa Rica, Dominican Republic, Ecuador, El Salvador, Guatemala, Honduras, Nicaragua, Panama, Peru, and the United States.
24GF Score

Get the complete analysis for PROCF

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price